Gossamer Bio

Q1 FY2026 EarningsGossamer Bio (GOSS) reported Q2 2026 preliminary cash of $57 million and confirmed a September 2026 NDA submission for seralutinib in PAH following a positive FDA Type B meeting. The company reacquired full worldwide rights to seralutinib by terminating its collaboration with Chiesi, receiving a $5 million settlement payment while granting Chiesi capped royalties. A successful debt exchange reduced the principal amount of 2027 Notes by 90.5% ($115.9 million), significantly strengthening the balance sheet ahead of potential FDA approval in Q3 2027.